Currently Viewing:
Newsroom
Currently Reading
Pfizer Announces Phase 3 Trial for Atopic Dermatitis Treatment
December 15, 2017 – Samantha DiGrande
Majority of Women With Breast Cancer Surgery Did Not Feel Fully Informed of Treatment Options
December 15, 2017 – Jaime Rosenberg
AJMC® in the Press, December 15, 2017
December 15, 2017 – AJMC Staff
What We're Reading: Medicare Lab Testing; CHIP Deadline; AMA Expands Diabetes Efforts
December 15, 2017 – AJMC Staff
5 Key Takeaways From ASH 2017
December 15, 2017 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: December 15, 2017
December 15, 2017
What We're Reading: Medical Device Tax; Marijuana and Vaping; Birth Control Without Prescriptions
December 14, 2017 – AJMC Staff
Study Finds Breathing Retraining Associated With Quality of Life Improvement for Patients With Asthma
December 14, 2017 – Laura Joszt
Rain and Pain Not Related, Harvard Researchers Say
December 13, 2017 – Allison Inserro

Decreasing Hospitalizations for COPD Patients With PAP Therapy

Alison Rodriguez
The majority of patients with chronic obstructive pulmonary disease (COPD) do not receive positive airway pressure (PAP) therapy despite its effectiveness in reducing hospitalizations, according to research.
The majority of patients with chronic obstructive pulmonary disease (COPD) do not receive positive airway pressure (PAP) therapy despite its effectiveness in reducing hospitalizations, according to research.

A new study utilized administrative claims data from the Truven Health MarketScan Database of hospitalizations among patients with COPD who received or did not receive PAP therapy. This includes continuous PAP, bilevel PAP, and noninvasive positive pressure ventilation with a home ventilator.

The study found that 92.5% of 1,881,652 patients with COPD were not using any type of PAP therapy. A minority of the patients received continuous PAP (5.6%), bilevel PAP (1.5%), and noninvasive positive pressure ventilation therapy (<1%). Of the patients who received these treatments, the administrative claims suggest a lower hospitalization risk than before the therapy was initiated compared with those who did not receive any therapy.

“Many clinicians still reference dated information when considering COPD treatment methods, yet technologies, machines, and even masks have advanced significantly since PAP therapy was first introduced,” Eli Diacopoulos, Philips Respiratory Care Business Leader, said in a statement. “This study demonstrates the vast opportunity for the industry to further adopt recent innovations for COPD treatment.”

The research also suggested greater benefits from PAP therapy are associated with comorbidities like sleep apnea, chronic respiratory failure, and heart failure.

“This analysis revealed that there is a solution already accessible within our toolbox that can keep patients out of the hospital, but it is significantly underutilized,” says Sairam Parthasarathy, MD, a professor of medicine and interim chief of Division of Pulmonary, Allergy, Critical Care and Sleep Medicine with University of Arizona College of Medicine. “With improved awareness and implementation of PAP therapy as a treatment for COPD, we can lower the cost burden for health systems while allowing patients to recover in the comfort of their own homes.”

The study acknowledged the need for further research through randomized controlled trials that can establish the causality between PAP therapy and reduced hospitalizations.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!